Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
5432848
Reference Type
Journal Article
Title
Exposure to phthalate-containing prescription drugs and the risk of colorectal adenocarcinoma: A Danish nationwide case-control study
Author(s)
Ennis, ZN; Pottegård, A; Ahern, TP; Hallas, J; Damkier, P
Year
2019
Is Peer Reviewed?
1
Journal
Pharmacoepidemiology and Drug Safety
ISSN:
1053-8569
EISSN:
1099-1557
Publisher
John Wiley and Sons Ltd
Volume
28
Issue
4
Page Numbers
528-535
Language
English
PMID
30793813
DOI
10.1002/pds.4759
Web of Science Id
WOS:000467999700016
URL
https://search.proquest.com/docview/2203079878?accountid=171501
Exit
Abstract
PURPOSE:
Some drug products contain phthalates as excipients, and in vitro studies have demonstrated that phthalates interfere with cellular mechanisms involved in colorectal cancer development. We therefore examined the association between cumulative phthalate exposure from drug products and risk of colorectal adenocarcinomas.
METHODS:
We used the Danish Cancer Registry to identify all patients with incident colorectal adenocarcinoma from 2008 to 2015 (n = 25 814). Each cancer case was matched to ten population controls. Linking information from Danish registers, we quantified cumulative phthalate exposure to the ortho-phthalates diethyl phthalate (DEP) and dibutyl phthalate (DBP) as well as enteric phthalate polymers from orally administered drugs. The association between cumulative phthalate exposure and colorectal cancer was estimated using conditional logistic regression.
RESULTS:
Cumulative exposure to ortho-phthalates exceeding 500 mg was associated with lower odds of colorectal cancer diagnosis (ORadj = 0.89; 95% CI, 0.81-0.96). Similar associations were observed for all DEP exposure exceeding 500 mg. Subgroup analysis excluding NSAID users, demonstrated that ortho-phthalate exposure was positively associated with colorectal cancer (ORadj = 1.26; 95% CI, 1.05-1.51).
CONCLUSION:
We found an apparent overall protective effect of cumulative phthalate exposure from drug excipients for colorectal adenocarcinoma. Omitting NSAID users reversed the signal and suggested a slightly increased risk associated with high cumulative ortho-phthalate exposure.
Keywords
Pharmacy And Pharmacology; colorectal neoplasms; Denmark; dibutyl phthalate; diethyl phthalate; excipients; pharmacoepidemiology; Phthalates; Identification methods; Subgroups; Exposure; Polymers; Health risk assessment; Adenocarcinoma; Colorectal carcinoma; Oral administration; Regression analysis; Prescription drugs; Colorectal cancer
Tags
IRIS
•
Diethyl phthalate (DEP)
Database searches
Jan 2020 update
PubMed
Web of Science
New for this project
Primary source of health effects
Human health effects studies
•
Phthalates – Targeted Search for Epidemiological Studies
Included
Source-March 2019 Update
WOS
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity